MOUNTAIN VIEW, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will participate in two healthcare conferences in May. NeuroPace management will participate in the Wells Fargo 2024 West Coast MedTech Tour at 2:30pm PT on Tuesday, May 28 in Menlo Park, CA. The format will be a fireside chat with a group of investors.
NeuroPace will also present at the Leerink Partners Healthcare Crossroads Conference, which takes place May 28-30, in Austin, TX. Joel Becker, NeuroPace’s Chief Executive Officer, will provide a corporate presentation on Thursday, May 30 at 8:00am CT, and management will participate in one-on-one meetings with investors during the conference. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available on the Events section of NeuroPace’s Investor website at https://investors.neuropace.com/news-and-events/events.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$10.43 |
Daily Change: | -0.54 -4.92 |
Daily Volume: | 150,582 |
Market Cap: | US$311.340M |
February 18, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load